Picharee Karunayawong is a researcher and economist at the Health Intervention and Technology Assessment Program Foundation (HITAP). Her work focuses on data-driven and quantitative research aimed at improving the efficiency of national health systems and reducing the use of low-value care. She works closely with the policymakers, participating in

Jarawee Sukmanee is a researcher at the Health Intervention and Technology Assessment Program Foundation (HITAP). With a background as a medical doctor and epidemiologist, she applies advanced analytical techniques to evaluate the cost-effectiveness of health interventions. She plays a key role in generating evidence to support national policy deci

Kumaree Pachanee Researcher of Foundation for Health Technology Assessment and Policy Evaluation (2020–Present)Kumaree holds a master’s degree in political economy and governance, (Political Science), from Burapha University. Since 2010, she has played a central role in research project management and policy research related to the development of h

Vilawan Luankongsomchit is a Researcher at the Health Intervention and Technology Assessment Program Foundation (HITAP). She holds a Bachelor of Science in Veterinary Technology from Kasetsart University and a Master of Science through a joint program between Kasetsart University and the University of Toulouse, France, specializing in One Health an

Pritaporn Kingkaew has been a researcher at HITAP since 2007. She graduated from a joint programme between Srinakharinwirot University, Thailand and the University of Nottingham, UK in 2007 with a Bachelor’s degree in Pharmacy. In 2009, she was awarded the HITAP scholarship to pursue a Master’s degree in Health Economics from the University of York

Yot Teerawattananon is a Assistant Secretary General of the Foundation & Senior Researcher of the Health Intervention and Technology Assessment Program (HITAP), which is a semi-autonomous research institute of Thailand’s Ministry of Public Health. The works of HITAP have been used to inform policy decisions regarding the adoption of medicines,

Dr. Wanrudee Isaranuwatchai is a Secretary General and Senior Researcher of the Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand. She is also an Affiliated Scientist at St. Michael’s Hospital, and an Associate Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, in Canada.H

Management of advanced prostate cancer, particularly in cases of metastatic castration-resistant prostate cancer (mCRPC), typically involves first-line treatment with the chemotherapeutic agent docetaxel. Nevertheless, disease progression following docetaxel therapy remains a major challenge, as there are currently no therapeutic options listed in

67196067RU034L6benefits package,Universal health coverage (UHC),National List of Essential Medicines (NLEM),Monitoring and evaluation,Policy development,Health system

Abstract During COVID-19 pandemic, telemedicine was a strategy to facilitate healthcare service delivery minimizing the risk of direct exposure among people. In Thailand, the National Health Security Office has included telemedicine services under the Universal Coverage Scheme to support social d